Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS
Healthcare Corporation (VITAS), one of the nation’s largest
providers of end-of-life care, and Roto-Rooter, the nation’s
largest commercial and residential plumbing and drain cleaning
services provider, reported financial results for its third quarter
ended September 30, 2020, versus the comparable prior-year period,
as follows:
Consolidated operating results:
- Revenue increased 9.9% to $528 million
- GAAP Diluted Earnings-per-Share (EPS) of $4.14, an increase of
16.3%
- Adjusted Diluted EPS of $4.86, an increase of 40.5%
VITAS segment operating results:
- Net Patient Revenue of $337 million, an increase of 4.8%
- Average Daily Census (ADC) of 19,045, a decline of 0.2%
- Admissions of 17,943 an increase of 4.7%
- Net Income, excluding certain discrete items, of $55.1 million,
an increase of 36.4%
- Adjusted EBITDA, excluding Medicare Cap, of $68.2 million, an
increase of 25.6%
- Adjusted EBITDA margin, excluding Medicare Cap, of 20.5%, an
increase of 367-basis points
Roto-Rooter segment operating results:
- Revenue of $191 million, an increase of 20.4%
- Net Income, excluding certain discrete items, of $36.2 million,
an increase of 25.5%
- Adjusted EBITDA of $51.8 million, an increase of 30.2%
- Adjusted EBITDA margin of 27.1%, an increase of 205-basis
points
VITAS
VITAS net revenue was $337 million in the third quarter of 2020,
which is an increase of 4.8%, when compared to the prior-year
period. This revenue increase is comprised primarily of a
geographically weighted average Medicare reimbursement rate
increase (including the suspension of sequestration on May 1, 2020)
of approximately 5.7%, a 0.2% decline in days-of-care, and acuity
mix shift which then reduced the blended average Medicare rate
increase 242-basis points. In addition, a reduction in Medicare Cap
liability increased revenue growth 162-basis points. The
combination of Medicaid net room and board pass-through and other
contra revenue activity increased revenue growth approximately
9-basis points in the quarter.
In the third quarter of 2020, VITAS reversed $4.1 million in
Medicare Cap billing limitations recorded in earlier quarters. This
compares favorably to the prior-year third quarter Medicare Cap
billing limitation of $1.3 million.
The federal government’s Medicare Cap billing limitation fiscal
year end is September 30. At September 30, 2020, VITAS had 30
Medicare provider numbers, four of which have an estimated fiscal
2020 Medicare Cap billing limitation liability of $8.7 million.
This compares favorably to the full year fiscal 2019 Medicare Cap
billing limitation liability of approximately $11.4 million.
Of VITAS’ 30 Medicare provider numbers, 22 provider numbers have
a Medicare Cap cushion of 10% or greater, one provider number has a
cap cushion between 5% and 10%, three provider numbers have a cap
cushion between 0% and 5%, and four provider numbers have a fiscal
2020 Medicare Cap billing limitation.
Average revenue per patient per day in the third quarter of 2020
was $194.10, which, including acuity mix shift, is 3.2% above the
prior-year period. Reimbursement for routine home care and high
acuity care averaged $166.51 and $971.71, respectively. During the
quarter, high acuity days-of-care were 3.4% of total days of care,
57-basis points less than the prior-year quarter. This 57-basis
point mix shift in high acuity days-of-care reduced the increase in
average revenue per patient per day from 5.7% to 3.2% in the
quarter.
The third quarter 2020 gross margin, excluding Medicare Cap and
excluding $7 million of costs for personal protection equipment
(PPE), disinfecting facilities and other incremental expenses
directly related to the pandemic, was 28.0%, which is a 465-basis
point margin improvement when compared to the third quarter of
2019. This increase in gross margin is attributed to a 2% increase
in reimbursement from the temporary suspension of sequestration, a
level-of-care mix shift to higher margin, lower reimbursement
routine home care and efficiencies from utilizing telehealth when
appropriate.
Selling, general and administrative expense was $21.8 million in
the third quarter of 2020, which is a favorable decrease of 0.8%
compared to the prior-year quarter. Adjusted EBITDA, excluding
Medicare Cap, totaled $68.2 million in the quarter, an increase of
25.6%. Adjusted EBITDA margin, excluding Medicare Cap, was 20.5% in
the quarter, which is a 367-basis point improvement when compared
to the prior-year period.
Roto-Rooter
Roto-Rooter generated quarterly revenue of $191 million in the
third quarter of 2020, an increase of $32.3 million, or 20.4%, over
the prior-year quarter. On a unit-for-unit basis, which excludes
the Oakland and HSW acquisitions completed in July 2019 and
September 2019, respectively, Roto-Rooter generated quarterly
revenue of $173 million for the third quarter of 2020, an increase
of 11.4% over the prior-year quarter.
Total commercial revenue, excluding acquisitions, decreased
11.6%. This aggregate unit-for-unit commercial revenue decline
consisted of drain cleaning revenue declining 13.0%, commercial
plumbing and excavation declining 11.2%, and commercial water
restoration declining 1.6%.
Total residential revenue, excluding acquisitions, increased
24.6%. This aggregate residential revenue growth consisted of
residential drain cleaning increasing 22.0%, plumbing and
excavation expanding 31.2%, and residential water restoration
increasing 16.1%.
Roto-Rooter started the second quarter of 2020 with weak
commercial and residential demand when compared to the prior year.
Fortunately, service demand began to improve in the later part of
April and continued to strengthen throughout the second quarter.
This positive trend continued throughout the third quarter with
unit-for-unit commercial revenue declining 15.7%, 8.5% and 10.7% in
July, August and September 2020, respectively. Unit-for-unit
residential revenue sales increased 22.8% in July, increased 24.1%
in August, and increased 26.6% in September 2020.
Roto-Rooter’s gross margin in the quarter was 51.6%, a 232-basis
point increase when compared to the third quarter of 2019. Adjusted
EBITDA in the third quarter of 2020 totaled $51.8 million, an
increase of 30.2%. The Adjusted EBITDA margin in the quarter was
27.1% which is a 205-basis point increase when compared to the
prior year. The increase in Adjusted EBITDA margin is attributed to
strong residential revenue growth which contribute slightly higher
margin than commercial revenue, as well as excellent expense
management on costs related to managing Roto-Rooter branch
infrastructure.
Chemed
Consolidated
As of September 30, 2020, Chemed had total cash and cash
equivalents of $113 million and no long-term debt.
In June 2018, Chemed entered into a five-year Amended and
Restated Credit Agreement that consists of a $450 million revolving
credit facility. The interest rate on this facility has a floating
rate that is currently LIBOR plus 100-basis points. At September
30, 2020, the Company had $38 million in outstanding letters of
credit resulting in approximately $412 million of undrawn borrowing
capacity under this credit agreement.
During the quarter, the Company repurchased 50,000 shares of
Chemed stock for $25.0 million which equates to a cost per share of
$499.48. As of September 30, 2020, there was approximately $207
million of remaining share repurchase authorization under this
plan.
Chemed restarted its share repurchase program in 2007. Since
that time Chemed has repurchased approximately 14.5 million shares,
aggregating approximately $1.4 billion at an average share cost of
$94.17. Including dividends over this period, Chemed has returned
approximately $1.6 billion to shareholders.
Guidance for
2020
Historically, Chemed earnings guidance has been developed using
previous years’ key operating metrics which are then modeled and
projected out for the calendar year. Critical within these
projections is the understanding of traditional patterned
correlations among key operating metrics. Once we complete this
phase of our projected operating results, we would then modify the
projections for the timing of price increases, changes in
commission structure, wages, marketing programs and a variety of
continuous improvement initiatives that our business segments plan
on executing over the coming year. This modeling exercise also
takes into consideration anticipated industry and macro-economic
issues outside of management’s control but are somewhat predictable
in terms of timing and impact on our business segments’ operating
results.
The 2020 pandemic has made accurate modeling and providing
meaningful earnings guidance for Chemed exceptionally challenging.
Federal, state and local government authorities are forced to make
swift decisions within our healthcare system, labor pools and
general economy. These governmental decisions have the potential
for an immediate and material impact on VITAS and Roto-Rooter
operating results.
Over the past seven months, Chemed has been able to successfully
navigate within this rapidly changing environment and produce
operating results that we believe provide us with the ability to
issue guidance for the remainder of the calendar year. However,
this guidance should be taken with the recognition the pandemic
will continue to materially disrupt all aspects of our healthcare
system and general economy to such an extent that future rules,
regulations and government mandates could materially impact our
ability to achieve this guidance.
Revenue growth for VITAS in 2020, prior to Medicare Cap, is
estimated to be 4%. Average Daily Census in 2020 is estimated to
expand approximately 1.3%. Full-year Adjusted EBITDA margin, prior
to Medicare Cap, is estimated to be 21%. We are currently
estimating $8.7 million for Medicare Cap billing limitations for
calendar year 2020. We also anticipate the $80.2 million of CARES
Act funds formulaically calculated by the federal government based
upon our 2019 Medicare fee-for-service revenue will be adequate to
cover increased costs specifically related to operating our
healthcare unit during the pandemic as well as any incremental
Medicare Cap billing limitations triggered from declines in
Medicare admissions. Chemed’s full year adjusted earnings per share
guidance eliminates any financial benefit from the CARES Act funds
that relate to lost revenue. We anticipate returning any unused
CARES Act funds to the federal government at the end of the
pandemic measurement period.
Roto-Rooter is forecasted to achieve full-year 2020 revenue
growth of 12.5% to 13.0%. Roto-Rooter’s Adjusted EBITDA margin for
2020 is estimated to be 26.1%.
Based upon the above, full-year 2020 adjusted earnings per
diluted share, excluding non-cash expense for stock options, tax
benefits from stock option exercises, costs related to litigation,
and other discrete items, is estimated to be in the range of $18.00
to $18.15 and compares to Chemed’s previous 2020 guidance of $16.20
to $16.40. This 2020 guidance assumes an effective corporate tax
rate of 25.8%. Chemed’s 2019 reported adjusted earnings per diluted
share was $13.95.
Conference Call
Chemed will host a conference call and webcast at 10 a.m., ET,
on Friday, October 30, 2020, to discuss the Company's quarterly
results and to provide an update on its business. The dial-in
number for the conference call is (844) 743-2500 for U.S. and
Canadian participants and +1 (661) 378-9533 for international
participants. The Conference ID is 8376498. A live webcast of the
call can be accessed on Chemed's website at www.chemed.com by
clicking on Investor Relations Home.
A taped replay of the conference call will be available
beginning approximately 24 hours after the call's conclusion. It
can be accessed by dialing (855) 859-2056 for U.S. and Canadian
callers and +1 (404) 537-3406 for international callers and will be
available for one week following the live call. The replay
Conference ID is 8376498. An archived webcast will also be
available at www.chemed.com.
Chemed Corporation operates in the healthcare field through its
VITAS Healthcare Corporation subsidiary. VITAS provides daily
hospice services to approximately 19,000 patients with severe,
life-limiting illnesses. This type of care is focused on making the
terminally ill patient's final days as comfortable and pain-free as
possible.
Chemed operates in the residential and commercial plumbing and
drain cleaning industry under the brand name Roto-Rooter.
Roto-Rooter provides plumbing, drain cleaning, and water cleanup
services through company-owned branches, independent contractors
and franchisees in the United States and Canada. Roto-Rooter also
has licensed master franchisees in the republics of Indonesia and
Singapore, and the Philippines.
This press release contains information about Chemed’s EBITDA,
Adjusted EBITDA and Adjusted Diluted EPS, which are not measures
derived in accordance with GAAP and which exclude components that
are important to understanding Chemed’s financial performance. In
reporting its operating results, Chemed provides EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS measures to help investors and
others evaluate the Company’s operating results, compare its
operating performance with that of similar companies that have
different capital structures and evaluate its ability to meet its
future debt service, capital expenditures and working capital
requirements. Chemed’s management similarly uses EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS to assist it in evaluating the
performance of the Company across fiscal periods and in assessing
how its performance compares to its peer companies. These measures
also help Chemed’s management to estimate the resources required to
meet Chemed’s future financial obligations and expenditures.
Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should
not be considered in isolation or as a substitute for comparable
measures calculated and presented in accordance with GAAP. We
calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by
service revenue and sales. A reconciliation of Chemed’s net income
to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is
presented in the tables following the text of this press
release.
Forward-Looking Statements
Certain statements contained in this press release and the
accompanying tables are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words "believe," "expect," "hope," "anticipate," "plan" and
similar expressions identify forward-looking statements, which
speak only as of the date the statement was made. Chemed does not
undertake and specifically disclaims any obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. These
statements are based on current expectations and assumptions and
involve various risks and uncertainties, which could cause Chemed's
actual results to differ from those expressed in such
forward-looking statements.
These risks and uncertainties arise from, among other things,
possible changes in regulations governing the hospice care or
plumbing and drain cleaning industries; periodic changes in
reimbursement levels and procedures under Medicare and Medicaid
programs; difficulties predicting patient length of stay and
estimating potential Medicare reimbursement obligations; challenges
inherent in Chemed's growth strategy; the current shortage of
qualified nurses, other healthcare professionals and licensed
plumbing and drain cleaning technicians; Chemed’s dependence on
patient referral sources; and other factors detailed under the
caption "Description of Business by Segment" or "Risk Factors" in
Chemed’s most recent report on form 10-Q or 10-K and its other
filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on such forward-looking
statements and there are no assurances that the matters contained
in such statements will be achieved.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATED
STATEMENTS OF INCOME (in thousands, except per share
data)(unaudited) Three Months Ended September 30, Nine
Months Ended September 30,
2020
2019
2020
2019
Service revenues and sales
$
528,297
$
480,613
$
1,546,294
$
1,416,231
Cost of services provided and goods sold
339,240
328,183
1,043,148
973,771
Selling, general and administrative expenses (aa)
88,317
76,836
243,413
222,421
Depreciation
11,714
10,147
34,761
29,744
Amortization
2,511
441
7,476
1,366
Other operating (income)/expenses
12,207
78
(28,935
)
9,001
Total costs and expenses
453,989
415,685
1,299,863
1,236,303
Income from operations
74,308
64,928
246,431
179,928
Interest expense
(379
)
(1,041
)
(2,005
)
(3,402
)
Other income--net (bb)
7,675
3,036
5,723
5,488
Income before income taxes
81,604
66,923
250,149
182,014
Income taxes
(13,882
)
(7,976
)
(44,435
)
(27,671
)
Net income
$
67,722
$
58,947
$
205,714
$
154,343
Earnings Per Share Net income
$
4.25
$
3.69
$
12.90
$
9.68
Average number of shares outstanding
15,940
15,970
15,948
15,952
Diluted Earnings Per Share Net income
$
4.14
$
3.56
$
12.53
$
9.35
Average number of shares outstanding
16,373
16,555
16,419
16,514
(aa) Selling, general and administrative ("SG&A")
expenses comprise (in thousands): Three Months Ended
September 30, Nine Months Ended September 30,
2020
2019
2020
2019
SG&A expenses before long-term incentive compensation and the
impact of market value adjustments related to deferred compensation
plans
$
79,287
$
72,273
$
232,797
$
212,775
Market value adjustments related to deferred compensation trusts
7,256
2,886
5,093
5,094
Long-term incentive compensation
1,774
1,677
5,523
4,552
Total SG&A expenses
$
88,317
$
76,836
$
243,413
$
222,421
(bb) Other income--net comprises (in thousands): Three
Months Ended September 30, Nine Months Ended September 30,
2020
2019
2020
2019
Market value adjustments related to deferred compensation trusts
$
7,256
$
2,886
$
5,093
$
5,094
Interest income
423
173
647
387
Other
(4
)
(23
)
(17
)
7
Total other income--net
$
7,675
$
3,036
$
5,723
$
5,488
CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATED
BALANCE SHEETS (in thousands, except per share data)(unaudited)
September 30,
2020
2019
Assets Current assets Cash and cash equivalents
$
112,765
$
9,066
Accounts receivable less allowances
110,839
114,480
Inventories
7,546
7,354
Prepaid income taxes
14,224
10,745
Prepaid expenses
25,222
26,150
Total current assets
270,596
167,795
Investments of deferred compensation plans held in trust
86,865
73,714
Properties and equipment, at cost less accumulated depreciation
181,386
172,932
Lease right of use asset
120,382
103,286
Identifiable intangible assets less accumulated amortization
120,401
129,276
Goodwill
578,519
576,600
Other assets
8,805
8,982
Total Assets
$
1,366,954
$
1,232,585
Liabilities Current liabilities Accounts payable
$
39,268
$
44,027
Accrued insurance
50,727
47,726
Accrued compensation
101,868
75,208
Accrued legal
9,561
7,283
Short-term lease liability
33,311
33,761
Unutilized CARES Act grant
48,041
-
Other current liabilities
46,387
43,496
Total current liabilities
329,163
251,501
Deferred income taxes
19,222
15,512
Long-term debt
-
130,000
Deferred compensation liabilities
86,875
73,335
Long-term lease liability
99,241
82,012
Other liabilities
31,045
7,845
Total Liabilities
565,546
560,205
Stockholders' Equity Capital stock
36,137
35,738
Paid-in capital
925,271
841,837
Retained earnings
1,615,465
1,365,303
Treasury stock, at cost
(1,777,809
)
(1,572,844
)
Deferred compensation payable in Company stock
2,344
2,346
Total Stockholders' Equity
801,408
672,380
Total Liabilities and Stockholders' Equity
$
1,366,954
$
1,232,585
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (in
thousands)(unaudited) For the Nine Months Ended September
30,
2020
2019
Cash Flows from Operating Activities Net income
$
205,714
$
154,343
Adjustments to reconcile net income to net cash provided by
operating activities: Unutilized CARES Act grant
48,041
-
Depreciation and amortization
42,237
31,110
Deferred payroll taxes
22,941
-
Stock option expense
13,296
10,729
Noncash long-term incentive compensation
5,301
4,184
Litigation settlement
2,684
6,000
Noncash directors' compensation
1,171
767
Deferred tax provision/(benefit)
831
(6,085
)
Amortization of debt issuance costs
229
229
Asset impairment loss
-
2,266
Changes in operating assets and liabilities, excluding amounts
acquired in business combinations: Decrease in accounts receivable
27,993
10,558
Increase in inventories
(84
)
(1,649
)
Increase in prepaid expenses
(2,072
)
(6,836
)
Increase in accounts payable and other current liabilities
34,526
28,622
Change in current income taxes
(4,366
)
(81
)
Net change in lease assets and liabilities
1,583
1,311
Increase in other assets
(9,646
)
(8,145
)
Increase in other liabilities
10,735
9,045
Other sources
1,298
1,277
Net cash provided by operating activities
402,412
237,645
Cash Flows from Investing Activities Capital expenditures
(42,670
)
(39,753
)
Business combinations
(3,600
)
(138,010
)
Other sources
672
101
Net cash used by investing activities
(45,598
)
(177,662
)
Cash Flows from Financing Activities Payments on revolving
line of credit
(264,900
)
(359,900
)
Proceeds from revolving line of credit
174,900
400,700
Purchases of treasury stock
(147,123
)
(71,926
)
Proceeds from exercise of stock options
31,498
23,383
Capital stock surrendered to pay taxes on stock-based compensation
(18,707
)
(26,108
)
Dividends paid
(15,639
)
(14,657
)
Change in cash overdrafts payable
(9,849
)
(7,535
)
Other (uses)/sources
(387
)
295
Net cash used by financing activities
(250,207
)
(55,748
)
Increase in Cash and Cash Equivalents
106,607
4,235
Cash and cash equivalents at beginning of year
6,158
4,831
Cash and cash equivalents at end of year
$
112,765
$
9,066
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME FOR THE THREE MONTHS
ENDED SEPTEMBER 30, 2020 AND 2019 (in thousands)(unaudited)
Chemed VITAS Roto-Rooter Corporate
Consolidated 2020 (a) Service revenues and sales $
337,097
$
191,200
$
-
$
528,297
Cost of services provided and goods sold
246,636
92,604
-
339,240
Selling, general and administrative expenses
21,799
48,074
18,444
88,317
Depreciation
5,592
6,089
33
11,714
Amortization
18
2,493
-
2,511
Other operating expense
9,052
3,155
-
12,207
Total costs and expenses
283,097
152,415
18,477
453,989
Income/(loss) from operations
54,000
38,785
(18,477
)
74,308
Interest expense
(47
)
(80
)
(252
)
(379
)
Intercompany interest income/(expense)
5,337
1,651
(6,988
)
-
Other income—net
381
38
7,256
7,675
Income/(loss) before income taxes
59,671
40,394
(18,461
)
81,604
Income taxes
(13,934
)
(9,218
)
9,270
(13,882
)
Net income/(loss) $
45,737
$
31,176
$
(9,191
)
$
67,722
2019 (b) Service revenues and sales $
321,748
$
158,865
$
-
$
480,613
Cost of services provided and goods sold
247,551
80,632
-
328,183
Selling, general and administrative expenses
21,965
41,758
13,113
76,836
Depreciation
5,105
5,003
39
10,147
Amortization
18
423
-
441
Other operating expense/(income)
97
(19
)
-
78
Total costs and expenses
274,736
127,797
13,152
415,685
Income/(loss) from operations
47,012
31,068
(13,152
)
64,928
Interest expense
(48
)
(80
)
(913
)
(1,041
)
Intercompany interest income/(expense)
4,618
2,234
(6,852
)
-
Other income—net
121
31
2,884
3,036
Income/(loss) before income taxes
51,703
33,253
(18,033
)
66,923
Income taxes
(11,930
)
(7,113
)
11,067
(7,976
)
Net income/(loss) $
39,773
$
26,140
$
(6,966
)
$
58,947
The "Footnotes to Financial Statements" are integral
parts of this financial information.
CHEMED CORPORATION AND
SUBSIDIARY COMPANIES CONSOLIDATING STATEMENTS OF INCOME
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019 (in
thousands)(unaudited)
Chemed VITAS
Roto-Rooter Corporate Consolidated 2020
(a) Service revenues and sales $
1,002,477
$
543,817
$
-
$
1,546,294
Cost of services provided and goods sold
772,880
270,268
-
1,043,148
Selling, general and administrative expenses
65,141
138,587
39,685
243,413
Depreciation
16,622
18,035
104
34,761
Amortization
53
7,423
-
7,476
Other operating (income)/expense
(31,661
)
2,725
1
(28,935
)
Total costs and expenses
823,035
437,038
39,790
1,299,863
Income/(loss) from operations
179,442
106,779
(39,790
)
246,431
Interest expense
(137
)
(272
)
(1,596
)
(2,005
)
Intercompany interest income/(expense)
14,463
4,422
(18,885
)
-
Other income—net
549
68
5,106
5,723
Income/(loss) before income taxes
194,317
110,997
(55,165
)
250,149
Income taxes
(47,055
)
(26,031
)
28,651
(44,435
)
Net income/(loss) $
147,262
$
84,966
$
(26,514
)
$
205,714
2019 (b) Service revenues and sales $
941,279
$
474,952
$
-
$
1,416,231
Cost of services provided and goods sold
728,397
245,374
-
973,771
Selling, general and administrative expenses
65,182
120,736
36,503
222,421
Depreciation
14,644
14,983
117
29,744
Amortization
53
1,313
-
1,366
Other operating expense
6,521
214
2,266
9,001
Total costs and expenses
814,797
382,620
38,886
1,236,303
Income/(loss) from operations
126,482
92,332
(38,886
)
179,928
Interest expense
(150
)
(273
)
(2,979
)
(3,402
)
Intercompany interest income/(expense)
13,395
6,609
(20,004
)
-
Other income—net
309
86
5,093
5,488
Income/(loss) before income taxes
140,036
98,754
(56,776
)
182,014
Income taxes
(33,636
)
(22,452
)
28,417
(27,671
)
Net income/(loss) $
106,400
$
76,302
$
(28,359
)
$
154,343
The "Footnotes to Financial Statements" are integral
parts of this financial information.
CHEMED CORPORATION AND
SUBSIDIARY COMPANIES CONSOLIDATING SUMMARIES OF EBITDA
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019 (in
thousands)(unaudited)
Chemed VITAS Roto-Rooter
Corporate Consolidated
2020
Net income/(loss) $
45,737
$
31,176
$
(9,191
)
$
67,722
Add/(deduct): Interest expense
47
80
252
379
Income taxes
13,934
9,218
(9,270
)
13,882
Depreciation
5,592
6,089
33
11,714
Amortization
18
2,493
-
2,511
EBITDA
65,328
49,056
(18,176
)
96,208
Add/(deduct): Intercompany interest expense/(income)
(5,337
)
(1,651
)
6,988
-
Interest income
(385
)
(38
)
-
(423
)
CARES Act grant
8,805
-
-
8,805
Direct costs related to COVID-19
6,945
1,321
-
8,266
Stock option expense
-
-
3,182
3,182
Litigation settlement
-
3,095
-
3,095
COVID-19 related Medicare cap
(2,250
)
-
-
(2,250
)
Long-term incentive compensation
-
-
1,774
1,774
Medicare cap sequestration adjustment
(852
)
-
-
(852
)
Adjusted EBITDA $
72,254
$
51,783
$
(6,232
)
$
117,805
2019
Net income/(loss) $
39,773
$
26,140
$
(6,966
)
$
58,947
Add/(deduct): Interest expense
48
80
913
1,041
Income taxes
11,930
7,113
(11,067
)
7,976
Depreciation
5,105
5,003
39
10,147
Amortization
18
423
-
441
EBITDA
56,874
38,759
(17,081
)
78,552
Add/(deduct): Intercompany interest expense/(income)
(4,618
)
(2,234
)
6,852
-
Interest income
(139
)
(34
)
-
(173
)
Acquisition expense
-
3,281
-
3,281
Stock option expense
-
-
2,711
2,711
Long-term incentive compensation
-
-
1,677
1,677
Medicare cap sequestration adjustment
859
-
-
859
Adjusted EBITDA $
52,976
$
39,772
$
(5,841
)
$
86,907
The "Footnotes to Financial Statements" are integral parts
of this financial information.
CHEMED CORPORATION AND SUBSIDIARY
COMPANIES CONSOLIDATING SUMMARIES OF EBITDA FOR THE
NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019 (in
thousands)(unaudited)
Chemed VITAS Roto-Rooter
Corporate Consolidated
2020
Net income/(loss) $
147,262
$
84,966
$
(26,514
)
$
205,714
Add/(deduct): Interest expense
137
272
1,596
2,005
Income taxes
47,055
26,031
(28,651
)
44,435
Depreciation
16,622
18,035
104
34,761
Amortization
53
7,423
-
7,476
EBITDA
211,129
136,727
(53,465
)
294,391
Add/(deduct): Intercompany interest expense/(income)
(14,463
)
(4,422
)
18,885
-
Interest income
(566
)
(68
)
(13
)
(647
)
Direct costs related to COVID-19
32,184
3,299
-
35,483
CARES Act grant
(32,184
)
-
-
(32,184
)
Stock option expense
-
-
13,296
13,296
Long-term incentive compensation
-
-
5,523
5,523
Litigation settlement costs
-
3,095
-
3,095
Medicare cap sequestration adjustment
619
-
-
619
Adjusted EBITDA $
196,719
$
138,631
$
(15,774
)
$
319,576
2019
Net income/(loss) $
106,400
$
76,302
$
(28,359
)
$
154,343
Add/(deduct): Interest expense
150
273
2,979
3,402
Income taxes
33,636
22,452
(28,417
)
27,671
Depreciation
14,644
14,983
117
29,744
Amortization
53
1,313
-
1,366
EBITDA
154,883
115,323
(53,680
)
216,526
Add/(deduct): Intercompany interest expense/(income)
(13,395
)
(6,609
)
20,004
-
Interest (income)/expense
(296
)
(91
)
-
(387
)
Stock option expense
-
-
10,729
10,729
Litigation settlement costs
6,000
-
-
6,000
Long-term incentive compensation
-
-
4,552
4,552
Acquisition expense
-
3,377
120
3,497
Medicare cap sequestration adjustment
3,063
-
-
3,063
Impairment loss on transportation equipment
-
-
2,266
2,266
Non cash ASC 842 expenses/(benefit)
656
55
(163
)
548
Adjusted EBITDA $
150,911
$
112,055
$
(16,172
)
$
246,794
The "Footnotes to Financial Statements" are integral parts
of this financial information.
CHEMED CORPORATION AND SUBSIDIARY
COMPANIES RECONCILIATION OF ADJUSTED NET INCOME (in
thousands, except per share data)(unaudited) Three Months
Ended Nine Months Ended September 30, September 30,
2020
2019
2020
2019
Net income as reported
$
67,722
$
58,947
$
205,714
$
154,343
Add/(deduct) pre-tax cost of: Direct costs related to COVID-19
8,266
-
35,483
-
CARES Act grant
8,805
-
(32,184
)
-
Stock option expense
3,182
2,711
13,296
10,729
Amortization of reacquired franchise agreements
2,352
331
7,056
1,103
Long-term incentive compensation
1,774
1,677
5,523
4,552
Litigation settlement
3,095
-
3,095
6,000
Medicare cap sequestration adjustments
(852
)
859
619
3,063
COVID-19 Medicare cap
(2,250
)
-
-
-
Impairment loss on transportation equipment
-
-
-
2,266
Acquisition expense
-
3,281
-
3,497
Non cash ASC 842 expenses
-
-
-
548
Add/(deduct) tax impacts: Tax impact of the above pre-tax
adjustments (1)
(5,351
)
(1,801
)
(6,165
)
(6,761
)
Excess tax benefits on stock compensation
(7,187
)
(8,792
)
(19,943
)
(18,737
)
Adjusted net income
$
79,556
$
57,213
$
212,494
$
160,603
Diluted Earnings Per Share As Reported Net income
$
4.14
$
3.56
$
12.53
$
9.35
Average number of shares outstanding
16,373
16,555
16,419
16,514
Adjusted Diluted Earnings Per Share Adjusted net income
$
4.86
$
3.46
$
12.94
$
9.73
Average number of shares outstanding
16,373
16,555
16,419
16,514
(1) The tax impact of pre-tax adjustments was calculated
using the effective tax rate of the operating unit for which each
adjustment is associated. The "Footnotes to Financial
Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES OPERATING
STATISTICS FOR VITAS SEGMENT (unaudited) Three Months
Ended September 30, Nine Months Ended September 30, OPERATING
STATISTICS
2020
2019
2020
2019
Net revenue ($000) (c) Homecare
$
278,856
$
274,746
$
826,954
$
800,059
Inpatient
27,633
23,599
85,983
69,063
Continuous care
30,699
29,446
105,836
92,476
Other
2,910
2,356
8,175
6,598
Subtotal
$
340,098
$
330,147
$
1,026,948
$
968,196
Room and board, net
(3,289
)
(2,846
)
(9,317
)
(8,098
)
Contractual allowances
(3,784
)
(4,236
)
(10,976
)
(10,904
)
Medicare cap allowance
4,072
(1,317
)
(4,178
)
(7,915
)
Net Revenue
$
337,097
$
321,748
$
1,002,477
$
941,279
Net revenue as a percent of total before Medicare cap allowance
Homecare
82.0
%
83.2
%
80.5
%
82.6
%
Inpatient
8.1
7.1
8.4
7.1
Continuous care
9.0
8.9
10.3
9.6
Other
0.9
0.8
0.8
0.7
Subtotal
100.0
100.0
100.0
100.0
Room and board, net
(1.0
)
(0.9
)
(0.9
)
(0.8
)
Contractual allowances
(1.1
)
(1.3
)
(1.1
)
(1.2
)
Medicare cap allowance
1.2
(0.4
)
(0.4
)
(0.8
)
Net Revenue
99.1
%
97.4
%
97.6
%
97.2
%
Days of care Homecare
1,426,191
1,361,508
4,192,681
3,961,261
Nursing home
261,396
315,566
844,232
909,318
Respite
4,566
8,582
15,416
21,552
Subtotal routine homecare and respite
1,692,153
1,685,656
5,052,329
4,892,131
Inpatient
27,017
30,553
84,907
89,366
Continuous care
33,013
39,670
110,200
125,397
Total
1,752,183
1,755,879
5,247,436
5,106,894
Number of days in relevant time period
92
92
274
273
Average daily census ("ADC") (days) Homecare
15,502
14,799
15,302
14,510
Nursing home
2,841
3,430
3,081
3,331
Respite
50
93
56
79
Subtotal routine homecare and respite
18,393
18,322
18,439
17,920
Inpatient
294
332
310
327
Continuous care
358
432
402
460
Total
19,045
19,086
19,151
18,707
Total Admissions
17,943
17,131
53,368
52,380
Total Discharges
18,205
16,915
51,281
51,274
Average length of stay (days)
97.1
92.6
92.9
91.6
Median length of stay (days)
14.0
17.0
14.0
16.0
ADC by major diagnosis Cerebro
35.1
%
35.7
%
35.7
%
35.9
%
Neurological
22.1
20.7
21.7
20.4
Cancer
12.5
12.9
12.6
12.9
Cardio
16.1
16.6
15.9
16.7
Respiratory
8.0
8.1
8.2
8.1
Other
6.2
6.0
5.9
6.0
Total
100.0
%
100.0
%
100.0
%
100.0
%
Admissions by major diagnosis Cerebro
21.4
%
21.1
%
21.2
%
20.8
%
Neurological
13.2
12.7
13.0
12.6
Cancer
27.4
30.5
27.8
29.2
Cardio
13.6
14.8
14.5
15.7
Respiratory
9.9
10.2
10.6
11.3
Other
14.5
10.7
12.9
10.4
Total
100.0
%
100.0
%
100.0
%
100.0
%
Estimated uncollectible accounts as a percent of revenues
1.1
%
1.3
%
1.1
%
1.1
%
Accounts receivable -- Days of revenue outstanding-excluding
unapplied Medicare payments
33.4
32.7
n.a.
n.a.
Days of revenue outstanding-including unapplied Medicare payments
22.1
21.0
n.a.
n.a.
The "Footnotes to Financial Statements" are integral parts
of this financial information.
CHEMED CORPORATION AND SUBSIDIARY
COMPANIES FOOTNOTES TO FINANCIAL STATEMENTS FOR THE
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019
(unaudited) (a) Included in the results of operations for
2020 are the following significant credits/(charges) which may not
be indicative of ongoing operations (in thousands):
Three Months
Ended September 30, 2020 VITAS Roto-Rooter
Corporate Consolidated CARES Act grant $
(8,805
)
$
-
$
-
$
(8,805
)
Direct costs related to COVID-19
(6,945
)
(1,321
)
-
(8,266
)
Stock option expense
-
-
(3,182
)
(3,182
)
Litigation settlement
-
(3,095
)
-
(3,095
)
Amortization of reacquired franchise agreements
-
(2,352
)
-
(2,352
)
COVID-19 Medicare cap
2,250
-
-
2,250
Long-term incentive compensation
-
-
(1,774
)
(1,774
)
Medicare cap sequestration adjustment
852
-
-
852
Pretax impact on earnings
(12,648
)
(6,768
)
(4,956
)
(24,372
)
Excess tax benefits on stock compensation
-
-
7,187
7,187
Income tax benefit on the above
3,253
1,794
304
5,351
After-tax impact on earnings $
(9,395
)
$
(4,974
)
$
2,535
$
(11,834
)
Nine Months Ended September 30, 2020 VITAS
Roto-Rooter Corporate Consolidated
Direct costs related to COVID-19 $
(32,184
)
$
(3,299
)
$
-
$
(35,483
)
CARES Act grant
32,184
-
-
32,184
Stock option expense
-
-
(13,296
)
(13,296
)
Amortization of acquired and cancelled franchise agreements
-
(7,056
)
-
(7,056
)
Long-term incentive compensation
-
-
(5,523
)
(5,523
)
Litigation settlement
-
(3,095
)
-
(3,095
)
Medicare cap sequestration adjustment
(619
)
-
-
(619
)
Pretax impact on earnings
(619
)
(13,450
)
(18,819
)
(32,888
)
Excess tax benefits on stock compensation
-
-
19,943
19,943
Income tax benefit on the above
157
3,564
2,444
6,165
After-tax impact on earnings $
(462
)
$
(9,886
)
$
3,568
$
(6,780
)
(b) Included in the results of operations for 2019 are the
following significant credits/(charges) which may not be indicative
of ongoing operations (in thousands):
Three Months Ended
September 30, 2019 VITAS Roto-Rooter
Corporate Consolidated Acquisition expense $
-
$
(3,281
)
$
-
$
(3,281
)
Stock option expense
-
-
(2,711
)
(2,711
)
Long-term incentive compensation
-
-
(1,677
)
(1,677
)
Medicare cap sequestration adjustment
(859
)
-
-
(859
)
Amortization of reacquired franchise agreements
-
(331
)
-
(331
)
Pretax impact on earnings
(859
)
(3,612
)
(4,388
)
(8,859
)
Excess tax benefits on stock compensation
-
-
8,792
8,792
Income tax benefit on the above
220
957
624
1,801
After-tax impact on earnings $
(639
)
$
(2,655
)
$
5,028
$
1,734
Nine Months Ended September 30, 2019 VITAS
Roto-Rooter Corporate Consolidated
Stock option expense $
-
$
-
$
(10,729
)
$
(10,729
)
Litigation settlement
(6,000
)
-
-
(6,000
)
Long-term incentive compensation
-
-
(4,552
)
(4,552
)
Acquisition expense
-
(3,377
)
(120
)
(3,497
)
Medicare cap sequestration adjustment
(3,063
)
-
-
(3,063
)
Impairment loss on transportation equipment
-
-
(2,266
)
(2,266
)
Amortization of reacquired franchise agreements
-
(1,103
)
-
(1,103
)
Non cash ASC 842 (expenses)/benefit
(656
)
(55
)
163
(548
)
Pretax impact on earnings
(9,719
)
(4,535
)
(17,504
)
(31,758
)
Excess tax benefits on stock compensation
-
-
18,737
18,737
Income tax benefit on the above
2,474
1,202
3,085
6,761
After-tax impact on earnings $
(7,245
)
$
(3,333
)
$
4,318
$
(6,260
)
(c) VITAS has 11 large (greater than 450 ADC), 21 medium
(greater than 200 but less than 450 ADC) and 17 small (less than
200 ADC) hospice programs. Of Vitas' 30 Medicare provider numbers,
for the current cap year, 22 provider numbers have a Medicare cap
cushion of 10% or greater, one provider numbers have a cap cushion
between 5% and 10%, three provider numbers have a cap cushion
between 0% and 5%, and four provider numbers have a Medicare cap
liability.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201029006123/en/
David P. Williams (513) 762-6901
Chemed (NYSE:CHE)
Historical Stock Chart
From Apr 2024 to May 2024
Chemed (NYSE:CHE)
Historical Stock Chart
From May 2023 to May 2024